Skip to main content

When your patient needs access to NULIBRY, immediate action is critical

Sentynl Cares | NULIBRY Access and Support program is your source for helping your patients receive NULIBRY—now and as they grow

At Sentynl Therapeutics, Inc., we strive to provide NULIBRY to children who need it, which is why we created Sentynl Cares | NULIBRY. It is a comprehensive set of support programs dedicated to helping children get access to NULIBRY. Sentynl Cares | NULIBRY also provides tools and resources to help facilitate the access process.

Sentynl Cares | NULIBRY is committed to providing affordability options for NULIBRY

When your patient joins Sentynl Cares | NULIBRY, they will have access to a variety of programs designed to help improve access to NULIBRY.

Sentynl Cares | NULIBRY also supports your patients by:

  • Conducting benefits investigations and providing support regarding prior authorizations and appeals
  • Offering a variety of patient support programs based on patients' insurance coverage and affordability challenges
  • Supplying educational resources
Sentynl Cares access support program logo

Sentynl Cares | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

If you have a suspected or confirmed patient with MoCD Type A, please call Sentynl Cares at

How to Get NULIBRY >



NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.



Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.


The most common side effects in NULIBRY-treated patients were infusion catheter–related complications, pyrexia (fever), viral infection, pneumonia, otitis media (ear infection), vomiting, cough/sneezing, viral upper respiratory infection (common cold/flu-like infection), gastroenteritis (stomach flu-like symptoms), diarrhea, and bacteremia (bacteria in the blood). Side effects for rcPMP-treated patients were similar to the NULIBRY-treated patients.


Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Please see full Prescribing Information for NULIBRY.